Novozymes achieves 8% organic sales growth in H1 2026

In Denmark, Novozymes reported an 8% organic sales growth in the first half of 2026. The company attributed this growth to increased volume, effective pricing, and synergies from innovations. Operating cash flow reached €523.3 million, a 23% increase year on year, prompting Novozymes to raise its full-year sales growth guidance to 7-8%. Strong demand in sectors like probiotics and dietary supplements contributed to this positive performance.